Compare BioNTech SE - ADR (BNTX) vs Colgate-Palmolive Company (CL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Colgate-Palmolive Company — how do they compare? BioNTech SE - ADR trades at $92.64 (market cap $23.31B), while Colgate-Palmolive Company trades at $92.22 (market cap $74.26B). The key difference: Colgate-Palmolive Company is far larger — about 3.2× BioNTech SE - ADR's market cap, and Colgate-Palmolive Company pays a 2.28% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | CL | |
|---|---|---|
Market Cap | $23.31B | $74.26B |
Sector | Health | Consumer Staples |
52-Week High | $119.34 | $99.14 |
52-Week Low | $83.89 | $74.98 |
Enterprise Value | $6.60B | $80.74B |
Dividend Yield | — | 2.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.67, up 2.72% today, with a bullish technical signal and strong analyst support. The stock faces fundamental challenges, including declining COVID-19 vaccine revenue and negative profitability, but holds a robust cash position of $16.78 billion. Recent news highlights leadership changes and pipeline advancements in oncology, with a consensus price target of $121.00 implying significant upside potential.
Outlook: Long-term growth hinges on oncology pipeline success, but near-term risks from vaccine demand volatility and net losses persist. Investment opportunity lies in discounted valuation relative to cash and pipeline assets, though execution risks and competitive pressures require careful monitoring.
Colgate-Palmolive (CL) trades at $93.27, up 0.29% on the day, with a bullish technical signal and consistent earnings beats. The company reported Q2 2026 EPS of $0.99, exceeding estimates, driven by strong margins and organic growth in emerging markets, though North American performance remains weak. Operating cash flow remains robust at $4.2 billion in 2025, supporting shareholder returns.
Outlook is mixed: valuation appears stretched with a P/E of 36.72, but analyst consensus targets $99.10. Risks include competitive pressures in North America and high debt levels. The stock offers a stable dividend, but growth concerns and insider selling warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Colgate-Palmolive Company
Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oral care line, the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries (international sales account for about 70% of its consolidated total, including approximately 45% from emerging regions). It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.
Read more on CL →
